Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Allakos Inc.

Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces a Restructuring to Focus on Development of AK006
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Appoints Neil Graham to its Board of Directors
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
From Allakos Inc.
Via GlobeNewswire
Tickers ALLK
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.